Research article · 12 Jun 2025
Conference abstractPublished 2017
Liposomes targeted with therapeutic antibodies: A potent tool in anticancer therapy
University of Wrocław, Poland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Nanoparticle-based drug formulations are expected to be more efficient and less toxic than conventional drug formulations. This is indeed true in case of the most widely used nanoparticles including liposomes, micelles, dendrim¬ers, nanotubes, and polymers. Moreover, most of the nanoparticle-based drug formulations offer a possibility of targeting the drug-loaded vehicles. Such strategy in case of anticancer drugs promises to be a hopeful strategy that allows reducing toxicity and minimizing adverse side effects. Targeting exploits the high affinity of cell-surface-targeted ligands, for specific retention and uptake by the targeted diseased cells. Methodology & Theoretical Orientation: In this short review, we would like to point to the application of liposomes as a versatile anticancer therapeutic carrier which can be targeted with antibodies directed against specific surface markers of cancer cells. Longcirculating liposomes containing PEG-PE and chemically activated PEG (e.g. maleimide derivative) may be considered as “Lego blocks”. Combining them with other components (i.e. drugs and surface-exposed molecules) in different configurations opens up multiple possibilities for different formulations of targeted anticancer drugs. They can be directed to specific tumor cells via targeting ligand(s) which could be attached covalently to the surface of liposomes. Prominent and relatively easy to apply as targeting agents are therapeutic antibodies and are already available on the market. Such liposomes may contain actively or passively encapsulated therapeutics of various natures. Conclusion & Significance: Two types of such nanocarriers were developed in our laboratory. One consists of BCL-2 antisense oligodeoxynucleotide complexed with cationic lipid or polyethyleneimine with anti CD20 antibody and the other is based on simvastatin carrying liposomes targeted with anti HER2 antibody. The former type of formulations fulfill criteria of size, stability, specificity and high efficacy against specific type of cancer cells without obvious side effects in both in vitro and in vivo studies. Liposomal formulation of simvastatin targeted with HER2 antibody proves promising vehicle to deliver relatively high amounts of simvastatin to HER2 overexpressing cells.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmaceutics & Drug Delivery Research.
Research article · 20 Feb 2025
Sustained Drug Delivery in Pharmaceutical Dosage Forms for Novel Approaches of Formulation Design
Research article · 23 Jan 2025
Cutting Out Counterfeits: How Blockchain Can Revolutionize Drug Traceability?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutics & Drug Delivery Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Aleksander F Sikorski”
- BylineArticles whose byline prints “Lucyna Matusewicz”
